Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
ABCG2 is a ubiquitous ATP-binding cassette transmembrane protein that is important in pharmacology and may play a role in stem cell biology and clinical drug resistance. To study the mechanism(s) regulating ABCG2 expression, we used ChIP to investigate the levels of acetylated histone H3, histone deacetylases (HDAC), histone acetyltransferases, and other transcription regulatory proteins associated with the ABCG2 promoter. Following selection for drug resistance and the subsequent overexpression of ABCG2, an increase in acetylated histone H3 but a decrease in class I HDACs associated with the ABCG2 promoter was observed. Permissive histone modifications, including an increase in histone H3 lysine 4 trimethylation (Me3-K4 H3) and histone H3 serine 10 phosphorylation (P-S10 H3), were observed accompanying development of the resistance phenotype. These changes mirrored those in some cell lines treated with a HDAC inhibitor, romidepsin. A repressive histone mark, trimethylated histone H3 lysine 9 (Me3-K9 H3), was found in untreated parental cells and cells that did not respond to HDAC inhibition with ABCG2 up-regulation. Interestingly, although all five studied cell lines showed global histone acetylation and MDR1 up-regulation upon HDAC inhibition, only those cells with removal of the repressive mark, and recruitment of RNA polymerase II and a chromatin remodeling factor Brg-1 from the ABCG2 promoter, showed increased ABCG2 expression. In the remaining cell lines, HDAC1 binding in association with the repressive Me3-K9 H3 mark apparently constrains the effect of HDAC inhibition on ABCG2 expression. These studies begin to address the differential effect of HDAC inhibitors widely observed in gene expression studies. (Mol Cancer Res 2008;6(1):151–64)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain
Bannister, A. J., Zegerman, P., Partridge, J. F., Miska, E. A., Thomas, J. O., Allshire, R. C., & Kouzarides, T. (2001) · Nature · doi:10.1038/35065138 · Cited by 2,903
Histone acetylation in chromatin structure and transcription
Grunstein, M. (1997) · Nature · doi:10.1038/38664 · Cited by 2,884 · cited 1×
“have been shown to induce a relaxed and competent or a condensed and inactive chromatin, respectively (50, 51), methylation of histones at key lysine residues seems to act cooperatively to generate a specific histone code to determine”
BackgroundActive Genes Are Tri-Methylated at K4 of Histone H3
Santos-Rosa, H., Schneider, R., Bannister, A. J., Sherriff, J., Bernstein, B. E., Emre, N. C. T., Schreiber, S. L., Mellor, J., & Kouzarides, T. (2002) · Nature · doi:10.1038/nature01080 · Cited by 2,138 · cited 2×
“domains, and is proposed to have a pivotal role in gene activation by providing a binding platform for different transcription factors (32).”
BackgroundHistone acetylation and transcriptional regulatory mechanisms
Struhl, K. (1998) · Genes & Development · doi:10.1101/gad.12.5.599 · Cited by 1,815 · cited 2×
“Brg-1, containing bromodomains, is thought to bind to acetylated histone tails with high affinity (51).”
BackgroundHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515 · cited 1×
“Whereas differential display (59) or microarray analyses (60, 61) identify only 2% to 10% of expressed genes as sensitive to HDAC inhibitors, in this case, we have a gene responding to HDAC inhibition in one cell line but not in another.”
BackgroundEvidence for nucleosome depletion at active regulatory regions genome-wide
Lee, C.-K., Shibata, Y., Rao, B., Strahl, B. D., & Lieb, J. D. (2004) · Nature Genetics · doi:10.1038/ng1400 · Cited by 738
Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin
Peters, A. H. F. M., Mermoud, J. E., O'Carroll, D., Pagani, M., Schweizer, D., Brockdorff, N., & Jenuwein, T. (2002) · Nature Genetics · doi:10.1038/ng789 · Cited by 502
Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs
Baker, E. K., Johnstone, R. W., Zalcberg, J. R., & El-Osta, A. (2005) · Oncogene · doi:10.1038/sj.onc.1208955 · Cited by 196 · cited 1×
“Histone hyperacetylation of MDR-1 was also noted following treatment with the HDAC inhibitor trichostatin A and some chemotherapeutic agents, including daunorubicin and etoposide (49).”
Cited by
Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.010 · Cited by 729
Liang, G., Zhu, Y., Ali, D. J., Tian, T., Xu, H., Si, K., Sun, B., Chen, B., & Xiao, Z. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0563-2 · Cited by 619
Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
Khalaf, K., Hana, D., Chou, J. T.-T., Singh, C., Mackiewicz, A., & Kaczmarek, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656364 · Cited by 513
Robey, R. W., To, K. K. K., Polgar, O., Dohse, M., Fetsch, P., Dean, M., & Bates, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.11.003 · Cited by 449
Self-citationEpigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K.-H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 422
Metadata
- Authors
- To, K. K. W., Polgar, O., Huff, L. M., Morisaki, K., & Bates, S. E.
- Venue
- Molecular Cancer Research
- Published
- 2008-01-01
- Volume
- 6
- Issue
- 1
- Pages
- 151-164
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2166424822
- Cited by
- 123
- References
- 8
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-07-0175
- The paper
- To, K. K. W., Polgar, O., Huff, L. M., Morisaki, K., & Bates, S. E. (2008). Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-07-0175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.